WallStreetZenWallStreetZen

NASDAQ: PDSB
Pds Biotechnology Corp Stock

$2.90+0.18 (+6.62%)
Updated Apr 18, 2024
PDSB Price
$2.90
Fair Value Price
$1.06
Market Cap
$106.37M
52 Week Low
$2.68
52 Week High
$10.27
P/E
-2.09x
P/B
4.07x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$42.94M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.27
Operating Cash Flow
-$34M
Beta
1.23
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A

PDSB Overview

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PDSB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PDSB ($2.90) is overvalued by 174.42% relative to our estimate of its Fair Value price of $1.06 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PDSB ($2.90) is not significantly undervalued (174.42%) relative to our estimate of its Fair Value price of $1.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PDSB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PDSB due diligence checks available for Premium users.

Be the first to know about important PDSB news, forecast changes, insider trades & much more!

PDSB News

Valuation

PDSB fair value

Fair Value of PDSB stock based on Discounted Cash Flow (DCF)
Price
$2.90
Fair Value
$1.06
Overvalued by
174.42%
PDSB ($2.90) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PDSB ($2.90) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PDSB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PDSB price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.09x
Industry
15.68x
Market
41.33x

PDSB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.07x
Industry
5.76x
PDSB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PDSB's financial health

Profit margin

Revenue
$0.0
Net Income
-$10.9M
Profit Margin
0%
PDSB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$59.4M
Liabilities
$33.3M
Debt to equity
1.27
PDSB's short-term assets ($59.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PDSB's short-term assets ($59.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PDSB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PDSB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$8.5M
Investing
$0.0
Financing
$10.8M
PDSB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PDSB vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
PDSB$106.37M+6.62%-2.09x4.07x
BRNS$105.48M+4.23%-1.42x0.56x
OTLK$107.88M-3.72%-2.07x-4.43x
ANVS$108.46M+9.57%-1.58x-13.99x
BLUE$104.20M-1.04%-1.59x0.47x

Pds Biotechnology Stock FAQ

What is Pds Biotechnology's quote symbol?

(NASDAQ: PDSB) Pds Biotechnology trades on the NASDAQ under the ticker symbol PDSB. Pds Biotechnology stock quotes can also be displayed as NASDAQ: PDSB.

If you're new to stock investing, here's how to buy Pds Biotechnology stock.

What is the 52 week high and low for Pds Biotechnology (NASDAQ: PDSB)?

(NASDAQ: PDSB) Pds Biotechnology's 52-week high was $10.27, and its 52-week low was $2.68. It is currently -71.76% from its 52-week high and 8.21% from its 52-week low.

How much is Pds Biotechnology stock worth today?

(NASDAQ: PDSB) Pds Biotechnology currently has 36,679,275 outstanding shares. With Pds Biotechnology stock trading at $2.90 per share, the total value of Pds Biotechnology stock (market capitalization) is $106.37M.

Pds Biotechnology stock was originally listed at a price of $258.80 in Oct 1, 2015. If you had invested in Pds Biotechnology stock at $258.80, your return over the last 8 years would have been -98.88%, for an annualized return of -42.96% (not including any dividends or dividend reinvestments).

How much is Pds Biotechnology's stock price per share?

(NASDAQ: PDSB) Pds Biotechnology stock price per share is $2.90 today (as of Apr 18, 2024).

What is Pds Biotechnology's Market Cap?

(NASDAQ: PDSB) Pds Biotechnology's market cap is $106.37M, as of Apr 19, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Pds Biotechnology's market cap is calculated by multiplying PDSB's current stock price of $2.90 by PDSB's total outstanding shares of 36,679,275.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.